The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

CRISPR crops, precision medicine could fuel 17.2% annual growth in North American gene-editing research

| October 28, 2019

“The growth of the genome editing market is primarily attributed to the rise in the production of genetically modified crops and rising prevalence of the genetic diseases,” according to the latest Genome Editing Market Growth Analysis Report. Overall, the market is expected to have a compound annual growth rate (CAGR) of 17.2% from 2018 to 2025. Despite rigid biosafety regulations on genome editing in the region, the emergence of markets centered on precision and regenerative medicines provides more growth opportunities for the North American genome editing market in the next couple of years.

The CRISPR segment, which dominated the genome editing market in 2017 with a share of 53.6%, is still expected to take up a significant portion of the market in 2025. Based on application, the cell line engineering segment is likewise foreseen to propel at a CAGR of 18.0%.

Related article:  ‘Patchwork’ of global gene editing regulations will harm seed production, group warns

Similarly, the genetic engineering segment will likely see a substantial increase due to extensive researches being done on its subsegments, particularly on animal and plant genetic engineering. With the advent of CRISPR, the biotechnology and pharmaceutical companies segment is also anticipated to dominate the market in 2025 as companies benefit from drug discoveries and enhanced research and development.

Read full, original article: Crop Biotech Update October 23, 2019

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend